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Abstract
Background: The prognosis of patients with pathologic stage T3a renal cell carcinoma (RCC) that is up-staged from
a small renal tumor remains controversial. We evaluated the prognosis of patients with RCC who were up-staged
from clinical stage T1 to pathologic stage T3a.
Methods: We retrospectively reviewed the data of 3431 patients who were surgically treated for clinical stage T1
RCC. The survival outcomes were compared using Kaplan-Meier and Cox proportional analyses.
Results: Among the clinical stage T1 patients, 215 (6.3%) were finally up-staged to pathologic stage T3a. Patient
age (HR 1.302, 95% CI 1.018–1.046, p < 0.001), tumor diameter (HR 1.686, 95% CI 1.551–1.834, p < 0.001), and hilar
location (HR 1.765, 95% CI 1.147–2.715, p = 0.010) were significantly associated with upstaging. Kaplan-Meier analyses
showed significantly shorter recurrence-free, cancer-specific and overall survivals (all p < 0.001) in patients who were
up-staged. Multivariate Cox analyses revealed pathologic upstaging as an independent predictor of shorter recurrence-
free (HR 2.195, 95% CI 1.459–3.300, p < 0.001), cancer-specific (HR 2.238, 95% CI 1.252–4.003, p = 0.007), and overall
survivals (HR 1.632, 95% CI 1.029–2.588, p = 0.037). Subgroup analysis of pathologic stage T3a showed no significant
difference in survival of the partial nephrectomy group when compared to the radical nephrectomy group (all p > 0.5).
Conclusions: Patients up-staged from clinical stage T1 to pathologic stage T3a RCC showed shorter survival outcomes
than those without upstaging. However, partial nephrectomy, compared with radical nephrectomy, showed comparable
outcomes in patients who were up-staged.
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Background
Renal cell carcinoma (RCC) is the most frequently diag-
nosed malignancy among renal tumors worldwide [1],
and its incidence continues to steadily increase in most
countries [2]. The advancements and penetration of
modern radiologic imaging tools, including computed
tomography (CT) and ultrasonography, have contributed
to the overall increase in the incidental detection of
RCC, particularly that of the localized disease [3]. A
recent, large epidemiologic study from the United States
showed that patients with loco-regional disease com-
prised over 80% of the RCC patient population [4].
Another study using the Surveillance, Epidemiology and
End Results (SEER) database also demonstrated that
there was a concomitant increase in asymptomatic small
RCC along with the overall increase in the incidence of
RCC [5]. The major guidelines of both the European
Association of Urology and the American Urologic
Association recommend partial nephrectomy as the pri-
mary treatment for clinical stage T1 RCC to facilitate
better preservation of renal function and equivalent
oncological control [6, 7].
However, there have been concerns regarding patients
who were initially diagnosed with a clinical stage T1
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renal tumor that was subsequently up-staged to a higher
pathologic stage, particularly following partial nephrec-
tomy. Previous studies have reported heterogeneous
oncological outcomes between patients who experienced
pathologic upstaging (clinical stage T1 to pathologic
stage T3a) and those who did not [8–11]. Some reported
similar survival outcomes between the two groups, while
others showed contradictory results. Another important
issue in this regard is the lack of unified application of
the recent TNM classification. Most previous studies
used the previous definition of TNM staging and/or did
not provide exact definitions for the pathologic stage
T3a. Therefore, we tried to evaluate the oncological
outcomes and exact prognosis of patients with clinical
stage T1 RCC in our cohort whose cancers were
upstaged from clinical stage T1 to pathologic stage T3a
after surgery using the recent definitions of the 2010
TNM classification.
Methods
After approval from the Institutional Ethical Review
Board, we retrospectively reviewed the medical records
of 3749 patients who underwent surgery between Janu-
ary 1997 and December 2016 for clinical stage T1 renal
tumors and who were diagnosed with RCC without any
evidence of metastasis. Renal biopsy was not routinely
performed even if the patients were scheduled to
undergo partial nephrectomy. If there were any suspi-
cious findings indicative of an advanced clinical stage,
such as venous invasion or thrombus, patients were
regarded as having disease higher than clinical stage T1,
and 203 patients were subsequently excluded from the
study. After the additional exclusion of 115 patients
(other malignancy [n = 57], lymph node invasion [n =
12], and incomplete information [n = 46]), we finally in-
cluded 3431 patients. The clinical and pathologic infor-
mation was retrieved from our prospectively maintained
database. The clinical stages were mainly determined
using preoperative abdominal CT. The preoperative
evaluation also included chest radiography (or CT) and
a bone scan. If needed, further evaluations, such as mag-
netic resonance imaging or ultrasonography, were also
performed. The clinical and pathologic stages were de-
termined according to the seventh edition of the TNM
classification of the American Joint Committee on Can-
cer [12]. We centrally reviewed the medical records of
patients who were initially staged according to the out-
dated TNM staging and reclassified them according to
the recent 2010 TNM classification. Nuclear grading
was performed using the Fuhrman’s grading system and
histologic subtypes were assessed using the Heidelberg
classification [13, 14]. Pathologic upstaging was defined
when the final pathology was determined as pathologic
stage T3a for clinical stage T1 renal tumors. When the
tumor was located in the renal hilum in close contact
with the renal vessels (≤0.5 cm), it was categorized as a
hilar tumor. We also classified the patients into three
groups according to the depth of the tumor, as in previ-
ous studies [15]. An exophytic tumor was defined when
≥60% of the tumor protruded externally from the paren-
chymal surface, an endophytic tumor was defined when
≥60% of the tumor was embedded inside the paren-
chyma, and all other tumors were defined as mesophytic
tumors. Disease recurrence was defined when there was
radiologic or pathologic evidence of local recurrence
and/or distant metastasis. Postoperative evaluations were
performed at 3- to 6-month intervals for the first 2 years
and annually thereafter. Information about patient mor-
tality was acquired from the database of the Korean Na-
tional Statistical Office and by review of our medical
records. Recurrence-free survival, cancer-specific sur-
vival, and overall survival were defined as the time from
the date of surgery to the date of recurrence, cancer-
specific mortality, or all-cause mortality, respectively.
We performed subgroup analyses to compare the onco-
logical outcomes between partial and radical nephrec-
tomy in the clinical stage T1a patients and in the clinical
stage T1 patients with pathologic upstaging.
An independent t-test and chi-square test were per-
formed to compare the perioperative characteristics
between the groups. Logistic regression tests were per-
formed for univariate and multivariate analyses and
Kaplan–Meier analysis with log-rank tests to evaluate
the differences in survival outcomes between the sub-
groups. Multivariate Cox-proportional hazard analysis
was performed to identify the possible predictors of each
survival outcome. The SPSS software package (SPSS 19.
0, Chicago, IL, USA) was used for the statistical analyses.
All p-values presented were two-sided and p < 0.05 was
considered statistically significant.
Results
The patients’ clinico-pathologic profiles are summarized
in Table 1. The median age was 55.0 years (interquartile
range (IQR) 46.0–65.0), the median tumor size was 3.
3 cm (IQR 2.0–4.4), and the median follow-up time was
39.0 months (IQR 15.0–69.0). There were 210 (6.1%) pa-
tients with hilar tumors, 944 (28%) patients with endo-
phytic tumors, 809 patients (24%) with mesophytic
tumors, and 1678 (49%) patients with exophytic tumors.
Partial nephrectomy was performed in 2071 (60%) pa-
tients and radical nephrectomy in 1360 (40%) patients.
After partial or radical nephrectomy, 215 (6.3%) patients
showed pathologic upstaging and no patients were
treated with adjuvant therapy for pathologic upstaging.
Comparison of the clinical characteristics of the two
groups revealed that patients with pathologic upstaging
were significantly older (p < 0.001), had significantly
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larger tumors (p < 0.001), had more co-morbidities,
such as diabetes mellitus (p = 0.028) or hypertension (p
= 0.001), and had a significantly higher prevalence of
hilar tumors (p < 0.001). Forty-seven (1.4%) patients
(five in the radical nephrectomy group and 42 in the
partial nephrectomy group) showed positive surgical
margins and four were upstaged to T3a (one in the
radical nephrectomy group and three in the partial
nephrectomy group). Although 11 patients were initially
intended to undergo partial nephrectomy, they were in-
evitably converted to radical nephrectomy. The patients
with pathologic upstaging also showed a significantly
higher nuclear grade than those without pathologic
upstaging (p < 0.001). The multivariate regression tests
showed that older age, larger tumor size, and hilar loca-
tion were significantly associated with pathologic
upstaging, whereas tumor depth did not show any sig-
nificant associations (Table 2).
Table 1 Summarization of clinical and pathologic characteristics of entire patients and according to the up-staging of pathologic









Median Age (y) 55.0 (46.0–65.0) 55.0 (46.0–65.0) 60 (52.0–69.0) < 0.001
Median BMI (kg/m2) 24.6 (22.6–26.7) 24.6 (22.6–26.7) 24.4 (22.7–26.7) 0.406
Gender (male) 2462 (72%) 2304 (72%) 158 (74%) 0.585
ECOG score (≥1) 802 (23%) 749 (23%) 53 (25%) 0.677
Diabetes mellitus 502 (15%) 459 (14%) 43 (20%) 0.028
Hypertension 1351 (40%) 1244 (39%) 107 (50%) 0.001
Tumour size (cm) 3.3 (2.0–4.4) 3.1 (1.9–4.1) 5.0 (3.7–6.2) < 0.001
Laparoscopy 1420 (41%) 1355 (42%) 85 (40%) 0.617
Type of nephrectomy < 0.001
Radical 1360 (40%) 1202 (37%) 158 (74%)
Partial 2071 (60%) 2014 (63%) 57 (27%)
Hilar location 210 (6.1%) 174 (5.4%) 36 (17%) < 0.001
Tumour location 0.204
Exophytic 1678 (49%) 1565 (49%) 113 (53%)
Mesophytic 809 (24%) 769 (24%) 40 (19%)
Endophytic 944 (28%) 882 (27%) 62 (29%)
Clinical stages < 0.001
cT1a 2462 (72%) 2379 (74%) 83 (39%)
cT1b 969 (28%) 837 (26%) 132 (61%)
Postoperative characteristics
Pathologic stage < 0.001
pT1 2406 (70%) 2406 (75%)
pT2 810 (24%) 810 (25%)
pT3a 215 (6.3%) 215 (100%)
Fuhrman grade < 0.001
≤2 1935 (56%) 1865 (58%) 70 (33%)
≥3 1496 (44%) 1351 (42%) 145 (67%)
Histologic subtype 0.234
Clear cell 2912 (85%) 2737 (85%) 175 (81%)
Papillary 238 (6.9%) 223 (6.9%) 15 (7.0%)
Chromophobe 236 (6.9%) 217 (6.7%) 19 (8.8%)
Collecting duct 6 (0.2%) 5 (0.2%) 1 (0.5%)
Unclassified 39 (1.1%) 34 (1.1%) 5 (0.1%)
BMI body mass index, ECOG Eastern Cooperative Oncology Group
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After a median of 32.0 months (IQR 12.0–59.8),
196 (5.7%) patients showed disease recurrence.
Among these 196 patients, 26 (13%) exhibited local
recurrence abutting the resection margin or renal
fossa, 169 (86%) presented with distant metastasis
(with or without local recurrence), and one patient
lacked information. Seventy-three cancer-specific mor-
talities occurred after a median of 43.0 months (IQR
18.5–92.5), and 156 overall mortalities occurred after
a median of 50.0 months (IQR 22.3–91.8) postopera-
tively. Patients with pathologic upstaging also showed
significantly shorter recurrence-free (p < 0.001), cancer--
specific (p < 0.001), and overall survivals (p < 0.001) (Fig.
1). Among patients with pathologic upstaging, 36 showed
disease recurrence (local recurrence, 4; distant metastasis,
32) after a median of 19.0 months (IQR 5.0–39.5), and 20
patients died from metastasis after a median of 28.
5 months (IQR 9.5–86.5). The percentage of patients
who had distant metastasis was significantly higher in
patients with pathologic upstaging compared to pa-
tients without pathologic upstaging (p < 0.001).
Multivariate Cox proportional analyses revealed
pathologic upstaging as an independent predictor of
shorter recurrence-free (HR 2.195, 95% CI 1.459–3.
300, p < 0.001), cancer-specific (HR 2.238, 95% CI 1.
252–4.003, p = 0.007), and overall survival (HR 1.632,
95% CI 1.029–2.588, p = 0.037) (Table 3). We per-
formed subgroup analyses in only 2462 patients with
clinical stage T1a RCC to compare the outcomes of
radical nephrectomy with those of partial nephrec-
tomy. Following Kaplan-Meier analyses, the partial
nephrectomy group (n = 1782) showed equivalent
oncological outcomes in terms of recurrence-free (p =
0.628) and cancer-specific survival (p = 0.101) com-
pared with the radical nephrectomy group (n = 679)
(Fig. 2). Moreover, patients who underwent partial
Table 2 Multivariate regression tests upon up-staging to pathologic stage T3a in 3431 patients surgically treated for localized renal
cell carcinoma
Adjusted with hilar location Adjusted with tumour shape
HR 95% CI p value HR 95% CI p value
Age 1.032 1.018–1.046 < 0.001 1.032 1.017–1.046 < 0.001
High BMI (≥24 kg/m2) 0.871 0.641–1.184 0.379 0.870 0.640–1.182 0.373
Gender (Female) 0.766 0.543–1.079 0.127 0.767 0.544–1.081 0.129
Diabetes mellitus (yes) 1.313 0.890–1.939 0.170 1.316 0.891–1.942 0.167
Hypertension (yes) 1.127 0.811–1.567 0.476 1.128 0.812–1.568 0.472
ECOG score (≥2) 0.567 0.238–1.355 0.202 0.575 0.241–1.376 0.214
Tumour size 1.686 1.551–1.834 < 0.001 1.726 1.588–1.877 < 0.001
Hilar location (yes) 1.765 1.147–2.715 0.010
Tumour location
Exophytic Reference
Mesophytic 0.805 0.539–1.202 0.288
Endophytic 1.318 0.925–1.879 0.126
HR hazard ratio, CI confidence interval, BMI body mass index, ECOG Eastern Cooperative Oncology Group
Fig. 1 Kaplan-Meier analysis for recurrence-free, cancer-specific, and overall survival between patients with and without pathologic upstaging
among the 3431 patients with clinical stage T1 renal cell carcinoma (a, recurrence-free survival; b, cancer-specific survival; c, overall survival)
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nephrectomy showed significantly longer overall sur-
vival compared with patients who underwent radical
nephrectomy (p = 0.022). Subsequently, we performed
another subgroup analysis in the cohort of pathologic
stage T3a patients (n = 215) who initially had clinical
stage T1 RCC and upstaged to pathologic stage T3a;
however, we could not find any significant differences
in recurrence-free, cancer-specific, or overall survivals
between the radical and partial nephrectomy groups
(all p > 0.05, Fig. 2).
Discussion
In the present study, approximately 6.3% among the pa-
tients with clinical stage T1 RCC were upstaged to
pathologic stage T3a after surgery. Furthermore, 17% of
these patients with pathologic upstaging experienced
disease recurrence, and 9.3% eventually died from the
disease. Even though the percentage of patients who ex-
perienced pathologic upstaging after surgery was rela-
tively low, a non-negligible percentage of these patients
showed adverse consequences. Finally, the patients with
Table 3 Multivariate analysis using the Cox proportional hazard model of possible predictors of recurrence-free, overall and cancer-
specific survivals after surgical treatments for localized renal cell carcinoma
Recurrence-free survival Overall survival Cancer-specific survival
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age 1.010 0.996–1.023 0.153 1.067 1.049–1.085 < 0.001 1.052 1.027–1.077 < 0.001
BMI (≥24 kg/m2) 0.834 0.623–1.115 0.219 0.682 0.491–0.948 0.023 0.732 0.451–1.189 0.207
Gender (Female) 0.832 0.592–1.168 0.288 0.834 0.574–1.210 0.339 0.842 0.494–1.437 0.529
Diabetes mellitus (yes) 0.930 0.599–1.443 0.746 1.797 1.244–2.595 0.002 2.124 1.251–3.606 0.005
Hypertension (yes) 1.094 0.792–1.510 0.586 1.022 0.717–1.457 0.903 1.110 0.651–1.894 0.701
ECOG score (≥1) 2.024 1.114–3.678 0.021 2.031 1.456–2.835 < 0.001 1.029 0.368–2.877 0.956
Tumour size 1.298 1.206–1.397 < 0.001 1.256 1.150–1.372 < 0.001 1.461 1.305–1.635 < 0.001
Fuhrman grade (≥3) 1.557 1.160–2.089 0.003 0.841 0.606–1.167 0.299 1.128 0.699–1.822 0.621
Pathologic up-staging to T3a 2.195 1.459–3.300 < 0.001 1.632 1.029–2.588 0.037 2.238 1.252–4.003 0.007
Cellular type (non-clear cell) 0.720 0.463–1.119 0.144 1.120 0.699–1.795 0.638 1.009 0.494–2.059 0.981
HR hazard ratio, CI confidence interval, BMI body mass index, ECOG Eastern Cooperative Oncology Group
Fig. 2 Kaplan-Meier analysis for recurrence-free, cancer-specific, and overall survivals between the type of surgery in patients with clinical stage
T1a renal cell carcinoma (a–c) and in the patients with upstaging to pathologic stage T3a renal cell carcinoma (d–f)
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pathologic upstaging showed significantly shorter
survival outcomes in terms of recurrence-free, cancer-
specific and overall survivals.
Previous studies in this field demonstrated conflicting
results. Roberts et al. retrospectively analyzed 186 clinical
stage T1 patients who underwent surgery at the Johns
Hopkins Hospital, and concluded that patients with
pathologic upstaging showed similar recurrence-free
survival compared to those without pathologic upstaging
[8]. However, their study utilized the 1997 TNM staging
system and pathologic stage T3a was only defined when
there were invasions of the adrenal gland and/or peri-
renal fat. Another study by Ramaswamy et al. reported
similar results after analyzing 494 patients with clinical
stage T1 RCC after median follow-up time of 50 months
[9]. They concluded that no disease recurrence occurred
in the patients with pathologic upstaging, and therefore,
pathologic upstaging was not associated with compro-
mised oncologic outcomes. In contrast, Gorin et al. ana-
lyzed 563 patients with clinical stage T1 RCC who
underwent robotic partial nephrectomy; they reported that
pathologic stage T3a was associated with significantly
shorter recurrence-free survival [10]. However, these
previous studies had limitations, such as relatively small
numbers of subjects and short follow-up periods.
The incidence of pathologic upstaging was also re-
ported to be variable. Gorin et al. reported the incidence
of pathologic upstaging as 4% of all clinical stage T1 pa-
tients [10], Ramaswamy et al. as 13% [9], and Roberts et
al. as 31% [8]. Recently, Nayak et al. analyzed a large
database of 1448 patients with clinical stage T1 RCC and
reported that pathologic upstaging was observed in 134
(9%) patients [11]. In the present study, the overall inci-
dence of pathologic upstaging in patients with clinical
stage T1 RCC was 6.3%, which is similar to other stud-
ies’ results. As these incidences of pathologic upstaging
are not high, our study clearly showed that patients with
pathologic upstaging have worse clinical outcomes than
those without pathologic upstaging. As partial nephrec-
tomy is the first treatment option in patients with clin-
ical T1a RCC, it is reasonable to question the oncologic
feasibility of partial nephrectomy given that patients with
pathologic upstaging have significantly worse clinical
outcomes than those without pathologic upstaging.
However, when we compared the oncologic outcomes
between partial and radical nephrectomy in the patients
with clinical stage T1a RCC, we could not find any
significant differences in recurrence-free and cancer-
specific survivals, suggesting that partial nephrectomy
can provide at least equivocal oncological outcomes in
patients with clinical T1a RCC, even with pathologic up-
staging. Therefore, since our results showed that the
incidence of pathologic upstaging was quite low, the ma-
jority of patients will still benefit from partial
nephrectomy. Considering that the main reason for par-
tial nephrectomy is the preservation of renal function
and ultimately an increase in survival, we also compared
overall survival between radical and partial nephrectomy.
The partial nephrectomy group showed significantly lon-
ger overall survival compared with the radical nephrec-
tomy group (p = 0.022). Furthermore, the subsequent
subgroup analyses performed only with up-staged T3a
patients showed no significant differences in each sur-
vival outcome (all p > 0.5). Other studies also previously
reported increased survival benefits of partial nephrec-
tomy in small RCC [16–19]. Thompson et al. analyzed
648 patients and concluded that overall survival was sig-
nificantly shorter in the radical nephrectomy group [16].
Weight et al. performed a retrospective study of 2608
patients with clinical stage T1 renal tumors, and found
significant survival advantages, along with an improved
preservation of postoperative renal function in the
partial nephrectomy group [17]. To the best of our
knowledge, the present study is the largest study of the
survival benefits of partial nephrectomy over radical
nephrectomy in patients with clinical stage T1 RCC.
When we evaluated the tumor morphologic character-
istics upon the occurrence of pathologic upstaging, we
found that the hilar location of the tumor was signifi-
cantly associated with an increased incidence of patho-
logic upstaging, whereas the depth of the tumor was not.
To date, a small number of studies have sought to
identify the preoperative risk factors associated with
pathologic upstaging in patients with clinical stage T1
RCC [8–11]; however, only a few of these studies have
tried to evaluate the impact of the tumor’s morpho-
logical characteristics. Gorin et al. performed a multi-
variate analysis, including tumor characteristics, such as
tumor diameter and hilar location, and reported that in-
creased age, a larger tumor, and hilar location were sig-
nificantly associated with pathologic upstaging [10]. Tay
et al. performed a retrospective analysis of a very small
cohort of 65 patients [20]. Even though they only ana-
lyzed a small number of patients, they included the R.E.
N.A.L nephrometry score in their analysis and con-
cluded that the tumor diameter, the central location
within polar lines, and the total nephrometry score were
significantly higher in patients with pathologic upstaging.
However, they could not perform further multivariate
analysis with other preoperative variables upon the oc-
currence of pathologic upstaging because of the small
number of subjects.
Our study has certain limitations, including some in-
herent weaknesses due to its retrospective nature. We
were unable to analyze the full spectrum of tumor mor-
phologic features using the R.E.N.A.L nephrometry
score. However, we attempted to evaluate the morpho-
logic characteristics of pathologic upstaging in terms of
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hilar location and depth of the tumor. The follow-up
period was not long enough to evaluate long-term
survival outcomes. Furthermore, the patients with
pathologic upstaging may have been more closely ob-
served after surgery compared with patients without
pathologic upstaging, which may have led to detection
bias. We re-staged all the patients who initially under-
went pathologic staging using the outdated TNM staging
system prior to the introduction of the revised 2010
TNM classification. This process involved a thorough
but retrospective central review of the initial pathologic
reports, rather than actual re-inspection of all pathologic
specimens, a major limitation of this study. In addition,
detailed pathologic information about the cause of up-
staging was not available. Finally, our study was only
performed in Korean patients, and our results should be
validated in other racial groups.
Conclusion
There is a small but non-negligible incidence of patho-
logic upstaging from clinical stage T1 to pathologic stage
T3a in patients with RCC. Factors such as patient age,
tumor size, and hilar location are associated with
upstaging. Patients with pathologic upstaging have a
shorter survival than those without pathologic upstaging.
However, partial nephrectomy does not compromise the
oncologic outcomes in patients with clinical stage T1a
RCC, even in the up-staged T3a patients. Thus, nephron
sparing using partial nephrectomy should be considered
in all patients diagnosed with small RCC.
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